Consumer medicine information

APO-Gliclazide Uncoated Tablets

Gliclazide

BRAND INFORMATION

Brand name

APO-Gliclazide

Active ingredient

Gliclazide

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using APO-Gliclazide Uncoated Tablets.

What is in this leaflet

This leaflet answers some common questions about gliclazide. It does not contain all the available information. It does not take the place of talking to your doctor, pharmacist or diabetes educator.

All medicines have risks and benefits. Your doctor has weighed the risks of you using this medicine against the benefits they expect it will have for you.

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

Keep this leaflet with the medicine. You may want to read it again.

What this medicine is used for

Gliclazide belongs to a group of medicines called sulfonylureas.

It is used to control blood glucose (sugar) in patients with Type II diabetes mellitus. This type of diabetes is also known as non-insulin-dependent diabetes mellitus (NIDDM) or maturity onset diabetes.

Gliclazide is used when diet and exercise are not enough to control your blood glucose.

Gliclazide can be used alone or together with other medicines for treating diabetes.

How it works

Glucose is used by the body as fuel, and all people have glucose circulating in their blood. In diabetes, levels of blood glucose are higher than is needed. This is called hyperglycaemia.

Gliclazide lowers high blood glucose by increasing the amount of insulin produced by your pancreas.

If your blood glucose is not properly controlled, you may experience hypoglycaemia (low blood glucose) or hyperglycaemia (high blood glucose). High blood glucose can lead to serious problems with our heart, circulation and/or kidneys.

It is very important to control high blood glucose whether or not you feel unwell. This really helps to avoid serious long-term health problems, which can involve the heart, eyes, circulation, and/or kidneys.

A section at the end of this leaflet contains advice about recognising and treating hyperglycaemia.

As with many medicines used for the treatment of diabetes, there is a possibility that blood glucose levels may become very low during treatment with gliclazide. This is called hypoglycaemia.

A section at the end of this leaflet contains advice about recognising and treating hypoglycaemia.

Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed this medicine for another reason.

This medicine is available only with a doctor's prescription.

This medicine is not addictive. There is not enough information to recommend the use of this medicine in children.

Before you take this medicine

There are some people who should not take gliclazide. Please read the lists below.

If you think any of these situations apply to you, or you have any questions, please consult your doctor, pharmacist, or diabetes educator.

When you must not take it

Do not take this medicine if you are allergic to:

  • gliclazide
  • other sulfonylureas
  • sulphonamides, such as sulfa antibiotics or thiazide diuretics
  • any of the ingredients listed at the end of this leaflet.

Some of the symptoms of an allergic reaction may include:

  • shortness of breath
  • wheezing or difficulty breathing
  • swelling of the face, lips, tongue, throat or other parts of the body
  • rash, itching or hives on the skin

Do not take this medicine if you have or have had any of the following medical conditions:

  • Type I diabetes mellitus (insulin dependent diabetes mellitus, also known as IDDM, or juvenile or growth onset diabetes)
  • unstable or brittle diabetes
  • diabetic acidosis or ketosis
  • diabetic coma or pre-coma
  • a history of repeated ketoacidosis or coma
  • severe kidney disease
  • severe liver disease.

Do not take this medicine if you are pregnant or plan to become pregnant or are breastfeeding.

Gliclazide may affect your developing baby if you take it during pregnancy. Your doctor will usually replace gliclazide with insulin while you are pregnant. It is not known whether gliclazide passes into human breast milk.

Do not take this medicine if you are using miconazole, a medicine used to treat fungal infections.

Do not take this medicine if you are taking medicines called phenylbutazone or danazol.

Do not take this medicine after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering. If it is expired or damaged, return it to your pharmacist for disposal.

If you are not sure whether you should start taking gliclazide, talk to your doctor.

Before you start to take it

Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.

Tell your doctor if you have or have had any of the following conditions:

  • kidney disease
  • liver disease
  • a growth in your pancreas, called an insulinoma
  • a history of diabetic coma
  • adrenal, pituitary or thyroid problems
  • heart failure
  • a condition called Glucose-6-Phosphate Dehydrogenase Deficiency (G6PD), lowering of haemoglobin level and breakdown of red blood cells (haemolytic anaemia) can occur.
  • you are pregnant or plan to become pregnant or are breastfeeding.
  • Your doctor can discuss with you the risks and benefits involved.

Tell your doctor if you have any medical condition, or do anything, that may increase the risk of hyperglycaemia (high blood glucose). This may include:

  • illness or feeling unwell (especially with fever or infection)
  • injury
  • surgery
  • taking less gliclazide than prescribed
  • doing less exercise than normal
  • eating more carbohydrates than normal

Tell your doctor if you have any medical condition, or do anything, that may increase the risk of hypoglycaemia (low blood glucose). This may include:

  • drinking alcoholic drinks
  • not eating regular meals, including breakfast
  • doing more exercise than usual
  • eating less carbohydrate than normal.
    Alcohol, diet, exercise, and your general health all strongly affect the control of your diabetes.

Tell your doctor if you are taking a medicine called a beta-blocker. Taking this medicine may mask the symptoms of diabetes.

Tell your doctor if you suffer from lactose intolerance or malabsorption. These tablets contain lactose

Taking other medicines

Tell your doctor, pharmacist or diabetes educator if you are taking any other medicines, including any that you get without a prescription from your pharmacy, supermarket or health food shop.

Some medicines and gliclazide may interfere with each other. These include:

  • miconazole or fluconazole, used to treat fungal infections
  • other medicines used to treat diabetes (e.g. biguanides and insulin)
  • some medicines used to treat high blood pressure and other heart conditions (e.g. beta-blockers, ACE inhibitors)
  • monoamine oxidase inhibitors (MAOIs), used for treating depression, Parkinson's Disease or infections
  • clofibrate, a medicine for lowering cholesterol
  • medicines used to treat arthritis, pain and inflammation (e.g. oxyphenbutazone, phenylbutazone, high dose salicylates)
  • some antibiotics (e.g. sulphonamides, tetracyclines, chloramphenicol
  • cimetidine and similar medicines used to treat acid reflux and stomach ulcers
  • diuretics, also known as fluid tablets (e.g. chlorothiazide)
  • alcohol

Some medicines may lead to high blood glucose levels (hyperglycaemia) by weakening the blood glucose-lowering effect of gliclazide. These include:

  • alcohol
  • some medicines for epilepsy (e.g. phenobarbitone)
  • some medicines for hormonal disturbances (e.g. danazol)
  • some medicines used for mental illness (e.g. chlorpromazine)
  • some hormones used in hormone replacement therapy and oral contraceptives (oestrogens and progestogens)
  • St John's wort, (hypericum perforatum), used to treat depression
  • salbutamol and terbutaline, medicines for asthma
  • barbiturates, medicines used for sedation
  • steroid medicines called glucocorticoids (e.g. prednisolone, cortisone)

Some medicines may lead to unstable blood glucose (low blood sugar and high blood sugar) when taken at the same time as gliclazide, especially in elderly patients. These include:

  • fluoroquinolone antibiotics (e.g. ciprofloxacin, norfloxacin or moxifloxacin)

Gliclazide may change the effects of some other medicines:

  • some medicines used to prevent blood clots (warfarin and similar medicines)

If you are taking any of these, you may need a different dose or you may need to take different medicines.

Remember to keep checking your blood glucose levels.

Drinking alcohol can also affect your blood glucose levels and how well gliclazide works.

Other medicines not listed above may also interact with gliclazide.

Ask your doctor or pharmacist if you are not sure if you are taking any of these medicines.

How to take this medicine

Follow all directions given to you by your doctor carefully. They may differ to the information contained in this leaflet.

If you do not understand the instructions on the box, ask your doctor or pharmacist for help.

How much to take

Your doctor will tell you how much of this medicine you should take. This will depend on your condition and whether you are taking any other medicines.

The starting dose is usually 40 mg (half a tablet) per day. This will be adjusted slowly over several weeks, depending on how well your body responds to the dose.

How to take it

Swallow the tablets whole with a glass of water. Tablets can be broken in half, however they should not be crushed or chewed.

Crushing or chewing the tablets may change the effectiveness of the tablet.

Taking these tablets with food can help to minimise the risk of hypoglycaemia.

Do not skip meals while taking these tablets.

When to take it

Take your medicine at about the same time each day, usually with breakfast. Taking it at the same time each day will have the best effect. It will also help you remember when to take them.

How long to take it for

Continue taking your medicine for as long as your doctor tells you.

Gliclazide can help control your diabetes but cannot cure it. Therefore you may have to take it for a long time.

Make sure you have enough of this medicine to last over weekends and holidays.

If you forget to take it

If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.

Otherwise, take it as soon as you remember (with food), then go back to taking your tablets as you would normally.

Missed doses can cause hyperglycaemia (high blood glucose).

Do not take a double dose to make up for the dose that you missed. If you double a dose, this may cause hypoglycaemia (low blood glucose).

If you are not sure what to do, ask your doctor or pharmacist.

If you have trouble remembering to take your medicine, ask your pharmacist for some hints to help you remember.

If you take too much (overdose)

Immediately telephone your doctor or the Poisons Information Centre (telephone 13 11 26) for advice, or go to Accident and Emergency at your nearest hospital, if you think that you or anyone else may have taken too much of this medicine. Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.

If you take too much gliclazide you may experience symptoms of hypoglycaemia (low blood glucose).

If not treated quickly, these symptoms may progress to loss of co-ordination, slurred speech, confusion, loss of consciousness and fitting.

At the first signs of hypoglycaemia (low blood glucose), raise your blood glucose quickly by following the instructions at the end of this leaflet.

If you experience any of these symptoms, immediately get medical help.

While you are taking this medicine

Things you must do

If you are about to be started on any new medicine, remind your doctor and pharmacist that you are taking gliclazide.

Tell any other doctors, dentists and pharmacists who are treating you that you take this medicine.

If you become pregnant while taking this medicine, tell your doctor immediately.

Tell your doctor if you are about to have any blood tests.

Tell your doctor if you are going to have surgery or are going into hospital.

Take your tablets exactly as your doctor has prescribed. Otherwise you may not get the full benefits from treatment.

Make sure you check your blood glucose levels regularly. This is the best way to tell if your diabetes is being controlled properly. Your doctor or diabetes educator will show you how and when to do this.

Make sure that you, your friends, family and work colleagues can recognise the symptoms of hypoglycaemia (low blood glucose) and hyperglycaemia (high blood glucose) and know how to treat them. Instructions at the end of this leaflet can help you with this.

Visit your doctor for regular blood tests and checks of your eyes, feet, kidneys, heart, circulation, blood, and blood pressure.

Follow carefully your doctor's advice on diet, drinking alcohol and exercise.

Tell your doctor immediately if you notice the return of any symptoms of hyperglycaemia that you had before starting gliclazide. These may include lethargy or tiredness, headache, thirst, passing large amounts of urine and blurred vision.

These may be signs that gliclazide is no longer working, even though you may have been taking it successfully for some time.

Things you must not do

Do not give this medicine to anyone else, even if they have the same condition as you.

Do not take your medicine to treat any other complaints unless your doctor or pharmacist tells you to.

Do not stop taking your medicine or change the dosage without first checking with your doctor.

Do not skip meals while taking gliclazide.

Things to be careful of

Be careful when driving or operating machinery until you know how this medicine affects you. Also, be careful not to let your blood glucose levels fall too low. Gliclazide may cause dizziness and drowsiness in some people. Hypoglycaemia may slow your reaction time and affect your ability to drive or operate machinery. A section at the end of this leaflet contains advice about recognising and treating hypoglycaemia.

Drinking alcohol can make this worse. If either of these occurs, do not drive, operate machinery or do anything else that could be dangerous. If you drink alcohol while taking gliclazide, you may get flushing, headache, breathing difficulties, rapid heartbeat, stomach pains or feel sick and vomit.

Protect your skin when you are in the sun, especially between 10am and 3pm. Gliclazide may cause your skin to be more sensitive to sunlight than it is normally. Exposure to sunlight may cause a skin rash, itching, redness, or severe sunburn.

If outdoors, wear protective clothing and use a 30+ sunscreen. If your skin does appear to be burning, tell your doctor immediately.

If you are travelling, it is a good idea to:

  • wear some form of identification showing you have diabetes
  • carry some form of sugar to treat hypoglycaemia if it occurs, for example, sugar sachets or jelly beans
  • carry emergency food rations in case of a delay, for example, dried fruit, biscuits or muesli bars
  • keep gliclazide readily available

If you become sick with a cold, fever or flu, it is very important to continue taking gliclazide, even if you feel unable to eat your normal meal.

If you have trouble eating solid food, use sugar-sweetened drinks as a carbohydrate substitute or eat small amounts of bland food. Your diabetes educator or dietician can give you a list of foods to use for sick days.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking gliclazide.

Gliclazide helps most people with diabetes, however it may have unwanted side effects. All medicines can have side effects. Sometimes they are serious but most of the time they are not. You may need medical attention if you get some of the side effects.

Do not be alarmed by the following list of side effects. You may not experience any of them.

Ask your doctor or pharmacist if you have any concerns.

Tell your doctor if you notice any of the following:

  • hypoglycaemia and hyperglycaemia.
    A section at the end of this leaflet contains advice about recognising and treating hypoglycaemia and hyperglycaemia
  • stomach upset with symptoms like feeling sick, heartburn, diarrhoea or constipation
  • headache, unusual weakness
  • runny or blocked nose, sneezing, facial pressure or pain, bronchitis, sore throat and discomfort when swallowing, coughing
  • arthralgia, back pain, arthrosis
  • dizziness
  • stomach upset with symptoms like feeling sick, stomach pain, vomiting, diarrhoea or constipation.
  • your vision may be affected for a short time especially at the start of treatment. This effect is due to changes in blood sugar levels
  • tiredness, weariness.
  • decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. These symptoms usually vanish when the treatment is discontinued.
  • Increase of some hepatic enzymes levels, and exceptionally a liver disease

The above list includes the more common side effects of your medicine.

Tell your doctor as soon as possible if you notice any of the following:

  • high blood pressure, chest pain
  • urinary tract infection, viral infection
  • sinus, throat or upper lung infection

The above list includes serious side effects that may require medical attention.

If any of the following happen, stop taking this medicine and tell your doctor immediately or go to the Accident and Emergency department at your nearest hospital:

  • shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, tongue, throat or other parts of the body; rash, itching or hives on the skin (symptoms of a severe allergic reaction)
  • decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. These symptoms usually vanish when the treatment is discontinued
  • increase of some hepatic enzymes levels, and exceptionally a liver disease
  • widespread blistering rash or peeling of the skin - may be the first sign of rare life-threatening conditions (e.g. Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and severe hypersensitivity reactions (DRESS).

As for other sulphonylureas, the following adverse events have been observed: cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (e.g. jaundice) which in most cases disappeared after withdrawal of the sulfonylurea but may lead to life-threatening liver failure in isolated cases.

If you notice anything else that is making you feel unwell - you should consult your doctor or pharmacist.

Other side effects not listed above may also occur in some people.

Storage and disposal

Storage

Keep the tablets in the pack until it is time to take them. If you take your medicine out of the pack it may not keep well.

Keep your medicine in a cool dry place where the temperature stays below 25°C.

Do not store your medicine, or any other medicine, in the bathroom or near a sink. Do not leave it on a window sill or in the car. Heat and dampness can destroy some medicines.

Keep this medicine where children cannot reach it. A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

Disposal

If your doctor tells you to stop taking this medicine or the expiry date has passed, ask your pharmacist what to do with any medicine that is left over.

Product description

What it looks like

White, round, flat-sided tablets with bevelled edges, engraved "APO" over "80" on one side, cross-scored on the other side.

Blister packs of 100 tablets. AUST R 80084

Ingredients

Each tablet contains 80 mg of gliclazide as the active ingredient.

It also contains the following:

  • croscarmellose sodium
  • magnesium stearate
  • colloidal anhydrous silica
  • lactose monohydrate
  • microcrystalline cellulose

This medicine does not contain gluten, sucrose, tartrazine or other azo dyes.

This medicine contains lactose as sugar.

Sponsor

Apotex Pty Ltd
16 Giffnock Avenue
Macquarie Park NSW 2113

Recognising and treating hypoglycaemia (low blood glucose)

Hypoglycaemia may occur during gliclazide treatment.

The first signs of hypoglycaemia may include weakness, trembling or shaking, sweating, anxiety, changes in heart rate or breathing, problems with sight, depression, aggression, nausea, vomiting, cheat pain, light-headedness, dizziness, headache or lack of concentration, irritability, tearfulness, hunger, and/ or numbness around the lips and tongue.

These symptoms can occur suddenly.

If not treated promptly, these may progress to:

  • loss of co -ordination
  • slurred speech
  • confusion
  • drowsiness
  • loss of consciousness or fitting.

At the first signs of hypoglycaemia take some sugar to raise your blood sugar level quickly.

Do this by taking one of the following:

  • 5-7 jelly beans
  • 3 teaspoons of sugar or honey
  • half a can of ordinary (non-diet) soft drink
  • 2-3 concentrated glucose tablets
  • a tube of glucose gel

Note that taking artificial sweeteners will NOT help raise your blood sugar levels.

Then take some extra carbohydrates such as plain biscuits, fruit or milk - unless you are within 10-15 minutes of your next meal. Taking this extra carbohydrate will help to prevent a second drop in your blood glucose level.

If not treated quickly, hypoglycaemia symptoms may progress to loss of co-ordination, slurred speech, confusion, fits or loss of consciousness.

If hypoglycaemia symptoms do not get better straight away after taking sugar, or the symptoms are severe or prolonged, then go to Accident and Emergency at your nearest hospital - if necessary by calling an ambulance.

Contact your doctor or diabetes educator for advice if you are concerned about hypoglycaemia.

Recognising and treating hyperglycaemia (high blood glucose)

Some people may feel fine when their glucose levels are high.

High blood glucose usually occurs more slowly than low blood glucose. Signs of high blood glucose may include:

  • tiredness or lethargy
  • lack of energy
  • thirst
  • passing large amounts of urine
  • headache
  • blurred vision.

If you notice symptoms of hyperglycaemia, or your blood sugar levels are high, tell your doctor immediately. You may need adjustments of the dose or type of medicines you are taking.

It is very important to control high blood glucose whether or not you feel unwell. This really helps to avoid serious long-term health problems, which can involve the heart, eyes, circulation, and/or kidneys.

If you experience any of the signs of hyperglycaemia (high blood glucose) contact your doctor or diabetes educator for advice immediately.

This leaflet was prepared in September 2020.

Published by MIMS November 2020

BRAND INFORMATION

Brand name

APO-Gliclazide

Active ingredient

Gliclazide

Schedule

S4

 

1 Name of Medicine

Gliclazide.

2 Qualitative and Quantitative Composition

Each tablet contains gliclazide 80 mg, as the active ingredient.

Excipients with known effect.

Lactose monohydrate.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Uncoated tablet.

Round, white, flat-sided tablets with bevelled edges, engraved "APO" over "80" on one side, cross-scored on the other side.

4 Clinical Particulars

4.1 Therapeutic Indications

Diabetes mellitus of the maturity onset type, which cannot be controlled by diet alone.

4.2 Dose and Method of Administration

For adult use only.
Gliclazide should be taken with food because there is increased risk of hypoglycemia if a meal is taken late, if an inadequate amount of food is consumed or if the food is low in carbohydrate. It is recommended that the medication be taken at breakfast time. If a dose is forgotten, the dose taken on the next day and should not be increased.
The daily dose may vary from 40 to 320 mg taken orally. The initial recommended dose is 40 mg (half tablet) daily even in elderly patients (≥ 65 years), and may be increased if necessary up to 320 mg (4 tablets) daily. Doses up to 160 mg daily may be taken in a single dose but preferably at the same time each morning. Doses in excess of 160 mg should be taken in divided doses in the morning and evening.
In general, the dosage will depend on the severity of the glycaemia with ongoing adjustments should be made in order to obtain the optimal response at the lowest dosage.
Treatment with gliclazide does not obviate the necessity of maintaining standard dietary regulations.

4.3 Contraindications

This medication is contraindicated in the following cases:
Hypersensitivity to gliclazide, other sulphonylureas, sulfonamides, or to any of the excipients (see Section 2 Qualitative and Quantitative Composition; Section 3 Pharmaceutical Form);
Type I diabetes, diabetic keto-acidosis, diabetic pre-coma and coma;
Severe renal or hepatic impairment: in these cases use of insulin is recommended;
Treatment with miconazole (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions);
Pregnancy and lactation (see Section 4.6 Fertility, Pregnancy and Lactation, Use in pregnancy, Use in lactation).
It is generally not recommended to use this agent in combination with phenylbutazone or danazol (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).

4.4 Special Warnings and Precautions for Use

Monitoring of diabetic state.

As with other antidiabetic therapies, patients must be under close medical supervision. Particular care must be taken during the initial period of stabilisation. Patients treated with gliclazide should be monitored regularly to ensure optimal control of the diabetic state, and where necessary, for adjustment of dosage.

Transferring to gliclazide.

Patients who have been previously treated with sulphonylureas or biguanides alone or in combination may be transferred to gliclazide. When gliclazide is administered as sole therapy to patients who have previously required combination therapy (e.g. biguanides and sulphonylureas), careful observation is essential during the transitional phase.
It is not generally recommended that insulin treated patients be transferred to gliclazide.

Patient awareness.

Comprehensive instructions must be given to the patient about the nature of the disease and what must be done to detect and prevent complications.

Acute complications such as severe trauma, fever, infection or surgery.

These acute complications provoke additional metabolic stress, which accentuate the predisposition to hyperglycaemia and ketosis. Patients presenting with such conditions may require insulin to maintain control. It is not appropriate to increase the dosage of gliclazide.

Hypoglycaemia.

The risks of hypoglycaemia, together with its symptoms, treatment and conditions that predispose to its development, should be explained to the patient and to family members. The patient should be informed of the importance of following dietary advice, of taking regular exercise, and of regular monitoring of blood glucose levels. Hypoglycaemia may occur following administration of sulphonylureas. Rarely cases may be severe and prolonged, and require hospitalisation where glucose infusion may need to be continued for several days.
Careful selection of patients and of the dose used, as well as provision of adequate information to the patient are necessary to avoid hypoglycaemic episodes.
The following factors may increase the risk of hypoglycaemia:
patient does not follow the doctor's treatment advice (particularly elderly patients);
malnutrition;
irregular mealtimes, skipping meals, periods of fasting or dietary changes;
imbalance between physical exercise and carbohydrate intake;
renal impairment;
severe hepatic impairment;
overdose of anti-diabetic agents;
certain endocrine disorders: thyroid disorders, hypopituitarism and adrenal impairment, concomitant administration of certain medicines (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).
This treatment should only be prescribed if the patient is likely to have a regular food intake (including breakfast). It is important to have a regular carbohydrate intake due to the increased risk of hypoglycaemia if a meal is delayed, an inadequate amount of food is consumed or the food is low in carbohydrate. Hypoglycaemia is more likely to occur during periods of low-calorie diet, following prolonged or strenuous exercise, following alcohol intake or during treatment with a combination of hypoglycaemic agents.

Poor blood glucose control.

Blood glucose control in treated patients may be affected by St. John's wort (Hypericum perforatum) preparations (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions) fever, trauma, infection or surgical intervention. It may be necessary to discontinue treatment and to administer insulin in these cases.
The efficacy of oral antidiabetic agents often decreases in the long term. This may be due to progression in the severity of the diabetes, or to a reduced response to treatment. This phenomenon is known as secondary failure and should be distinguished from primary failure, when the drug is ineffective as first-line treatment. However, before classifying the patient as a secondary failure, dose adjustment and reinforcement of dietary measures should be considered.

Unstable blood glucose level (dysglycaemia).

Disturbances in blood glucose, including hypoglycaemia and hyperglycaemia have been reported, in diabetic patients receiving concomitant treatment with fluoroquinolones, especially in elderly patients. Indeed, careful monitoring of blood glucose is recommended in all patients receiving gliclazide and a fluoroquinolone at the same time.

Renal and hepatic impairment.

Severe renal or hepatic impairment may affect the distribution of gliclazide and hepatic impairment may also reduce the capacity for neoglucogenesis. These two effects increase the risk of severe hypoglycaemic reactions. A hypoglycaemic episode in these patients may be prolonged and appropriate management should be initiated.

Glucose-6-phosphate dehydrogenase deficiency (G6PD).

Treatment of patients with G6PD-deficiency with sulphonylurea agents can lead to haemolytic anaemia. Since gliclazide belongs to the chemical class of sulphonylurea drugs, caution should be used in patients with G6PD-deficiency and a non-sulphonylurea alternative should be considered.

Lactose intolerance.

Due to the presence of lactose, patients with rare hereditary problems of galactose intolerance, glucose galactose malabsorption, or the Lapp lactase deficiency should not take this medicinal product.

Use in the elderly.

See Section 4.2 Dose and Method of Administration.

Paediatric use.

See Section 4.2 Dose and Method of Administration.

Effects on laboratory tests.

Glycated haemoglobin should be monitored regularly. Blood glucose measurement may also be useful.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Blood glucose monitoring during and after treatment is necessary when gliclazide is used with medicines which can interact with gliclazide. It may also be necessary to adjust the dose of gliclazide during and after treatment with such medicines.

The following medications are likely to increase the risk of hypoglycaemia.

Concomitant use which is contraindicated.

Miconazole (systemic route, oromucosal gel).

Increases the hypoglycaemic effect with possible onset of hypoglycaemia symptoms or even coma.

Concomitant use which is not recommended.

Phenylbutazone (systemic route).

Increases the hypoglycaemic effect of sulphonylureas (displaces their binding to plasma proteins and/or reduces their elimination).
It is preferable to use a different anti-inflammatory agent, or else to warn the patient and emphasise the importance of self-monitoring. Where necessary, adjust the dose during and after treatment with the anti-inflammatory agent.

Alcohol.

Acute alcohol intoxication potentiates the hypoglycaemic action of all sulphonylurea agents by inhibiting compensatory reactions. This can lead to the onset of hypoglycaemic coma. Ingestion of alcohol may also cause a disulfiram-like reaction with characteristic flushing of the face, throbbing headache, giddiness, tachypnoea, tachycardia or angina pectoris.
Chronic alcohol abuse may, as a result of liver enzyme induction, increase the metabolism of sulphonylurea drugs, shortening the plasma half-life and duration of action.
Avoid alcohol or medicines containing alcohol.

Concomitant use which requires special care.

Potentiation of the blood glucose lowering effect and therefore in some instances, hypoglycaemia may occur when one of the following medications is taken: other antidiabetic agents (insulins, acarbose, biguanides, metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists), sulfonamides, clarithromycin, clofibrate, salicylates (high doses), chloramphenicol, MAOIs, β-blockers, H2-receptor antagonists, ACE inhibitors, fluconazole, nonsteroidal anti-inflammatory agents.

The following medications may cause an increase in blood glucose levels.

Advise the patient and emphasise the importance of glucose monitoring.

Concomitant use which is not recommended.

Danazol.

If the use of danazol cannot be avoided, it may be necessary to adjust the dose of gliclazide during and after treatment with danazol.

Concomitant use which requires special care.

Chlorpromazine.

High doses (> 100 mg per day of chlorpromazine) can increase blood glucose levels (reduced insulin release).
Advise the patient and emphasise the importance of glucose monitoring. It may be necessary to adjust the dose of gliclazide during and after treatment with chlorpromazine.

Glucocorticoids (systemic and local route: intra-articular, cutaneous and rectal preparations) and tetracosactrin.

Concomitant use may increase blood glucose levels with possible ketosis (glucocorticoids cause reduced tolerance to carbohydrates). Emphasize the importance of blood glucose monitoring, particularly at the start of treatment. It may be necessary to adjust the dose of Gliclazide during and after treatment with glucocorticoids.

Salbutamol, terbutaline (intravenous).

May cause increased blood glucose levels due to β2 agonist effects. If necessary, switch to insulin.

Barbiturates, oestrogens and progestogens.

May adversely affect blood sugar control with hypoglycaemic agents in some patients by causing increased blood glucose levels.

St John's wort (Hypericum perforatum) preparations.

Gliclazide exposure is decreased by St John's Wort (Hypericum perforatum).

The following products may cause unstable glucose.

Concomitant use which requires special care.

Fluroquinolones.

In case of a concomitant use of gliclazide and a fluoroquinolone, the patient should be warned of the risk of unstable blood glucose, and the importance of blood glucose monitoring should be emphasised.

Concomitant use to be taken into consideration.

Anticoagulant therapy (warfarin).

Sulphonylureas may lead to potentiation of anticoagulation during concurrent treatment. Adjustment of warfarin may be necessary.

4.6 Fertility, Pregnancy and Lactation

Effect on fertility.

No data available.
(Category C)
Gliclazide is contraindicated during pregnancy and insulin is the drug of first choice for treatment of diabetes during pregnancy. Treatment should be changed from gliclazide to insulin therapy before pregnancy is attempted, or as soon as pregnancy is discovered. Control of diabetes should be achieved before the time of conception to reduce the risk of congenital abnormalities linked to uncontrolled diabetes.
The sulphonylureas may enter the foetal circulation and cause neonatal hypoglycaemia.
Gliclazide should not be used in pregnant women. From a clinical point of view, there are limited data (less than 300 pregnancies) to allow evaluation of the possible malformative or foetotoxic effects of gliclazide, when administered during pregnancy.
It is not known whether gliclazide or its metabolites are excreted in breast milk. Given the risk of neonatal hypoglycaemia, gliclazide is contraindicated in women who are breast feeding. A risk to newborns/infants cannot be excluded.

4.7 Effects on Ability to Drive and Use Machines

Patients should be made aware of the signs and symptoms of hypoglycaemia and should be careful if driving or operating machinery, especially at the beginning of treatment.

4.8 Adverse Effects (Undesirable Effects)

Adverse reactions have occurred in some 12% of cases in clinical studies. However, approximately 2% of patients were withdrawn from therapy because of adverse reactions, notably hypoglycaemia, gastrointestinal disturbances (constipation, nausea, epigastric discomfort and heartburn), dermatological reactions (rash and transient itching), and biochemical abnormalities (elevated serum creatinine, increased serum alkaline phosphatase, raised serum AST, elevated BUN and raised serum bilirubin). Headache, slight disulfiram like reactions and lassitude have also been reported.
Serious reactions which have been reported with other sulphonylureas are leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, haemolytic anaemia, cholestatic jaundice and gastrointestinal haemorrhage. These reactions have not been reported with gliclazide (see also Class effects).

Hypoglycaemia (see Section 4.3 Contraindications; Section 4.4 Special Warnings and Precautions for Use; Section 4.9 Overdose).

The most frequent adverse reaction with gliclazide is hypoglycaemia.
As is the case with all sulphonylurea drugs, hypoglycaemic reactions have been reported following gliclazide administration. However, a number of studies have shown that hypoglycaemia is less common with gliclazide than with glibenclamide.
In long-term comparative studies, the percentage of patients experiencing hypoglycaemic episodes was similar between patients treated with gliclazide MR (11.6%) and those treated with gliclazide 80 mg (11.1%).
Possible symptoms of hypoglycaemia are: headache, intense hunger, nausea, vomiting, lassitude, sleep disorders, agitation, aggression, poor concentration, reduced awareness and slowed reactions, depression, confusion, visual and speech disorders, aphasia, tremor, paresis, sensory disorders, dizziness, feeling of powerlessness, loss of self-control, delirium, convulsions, shallow respiration, bradycardia, drowsiness and loss of consciousness, possibly resulting in coma and/or death.
In addition, symptoms of adrenergic counter-regulation may be observed: sweating, clammy skin, anxiety, tachycardia, hypertension, palpitations, angina pectoris and cardiac arrhythmia.
Usually, symptoms disappear after intake of carbohydrate such as sugar (artificial sweeteners have no effect). Experience with other sulphonylureas shows that hypoglycaemia can recur even when these measures are initially effective. If a hypoglycaemic episode is severe or prolonged, and even if it is temporarily controlled by intake of sugar, immediate medical treatment or even hospitalisation is required.
Severe hypoglycaemia, though very rarely reported, may occur in patients receiving gliclazide.
Adverse events that were reported in at least 2.0% of patients, in long-term controlled clinical studies, are presented in Table 1. The most frequent adverse events were not specifically related to the disease (such as respiratory infections or back pain).

Other adverse effects reported with gliclazide.

Gastrointestinal disturbances (reported with gliclazide), including nausea, dyspepsia, diarrhoea, abdominal pain, vomiting, and constipation may be avoided or minimised if gliclazide is taken with breakfast.
The following adverse effects have been rarely reported:

Skin and subcutaneous tissue disorders.

Pruritus, urticaria, maculopapular rashes, rash, angioedema, erythema and bullous reactions (such as Stevens-Johnson Syndrome [SJS] and toxic epidermal necrolysis [TEN]) (as with other sulfur-containing medications) and exceptionally, drug rash with eosinophilia and systemic symptoms (DRESS).

Blood and lymphatic system disorders (as with other sulphonylurea medications).

Anaemia, leucopenia, thrombocytopenia and agranulocytosis. These are in general reversible upon discontinuation of medication.

Hepatobiliary disorders.

Elevations of serum bilirubin and hepatic enzymes (AST, ALT, alkaline phosphatase) levels, and exceptionally, hepatitis (isolated reports). Treatment should be discontinued if cholestatic jaundice appears. These symptoms usually disappear after discontinuation of treatment.

Investigations.

Occasional elevations of serum creatinine, blood urea nitrogen.

Eye disorders.

Transient visual disturbances may occur due to changes in blood glucose levels, particularly on initiation of treatment. As with any glucose-lowering medication, transient visual disturbances may occur on initiation of treatment due to changes in blood glucose levels.

Class effects.

The following adverse events have been observed with sulphonylureas: cases of erythrocytopenia, agranulocytosis, haemolytic anaemia, pancytopenia and allergic vasculitis, hyponatraemia, elevated liver enzyme levels and even impairment of liver function (e.g. with cholestasis and jaundice) and hepatitis which regressed after withdrawal of the sulphonylurea or led to life-threatening liver failure in isolated cases.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

Overdose of sulphonylureas may cause hypoglycaemia.

Symptoms.

Manifestations of severe hypoglycaemia result from overdosage. Hypoglycaemia caused by sulphonylurea agents differs in several aspects from insulin coma. Warning symptoms are often absent, neurological syndromes are frequent and coma is often prolonged.

Treatment.

Moderate symptoms of hypoglycaemia (without loss of consciousness or neurological signs), should be corrected by carbohydrate intake, dose adjustment and/or modification of diet. Strict monitoring should be continued until the doctor is sure that the patient is out of danger.
Severe hypoglycaemic reactions are possible (with coma, convulsions or other neurological disorders) and must be treated as a medical emergency, requiring immediate hospitalisation.
If hypoglycaemic coma is diagnosed or suspected, the patient should be given a rapid I.V. injection of 50 mL of concentrated glucose solution (20 to 30%). This should be followed by continuous infusion of a more dilute glucose solution (10%) at a rate necessary to maintain blood glucose levels above 5 mmol/L. It is recommended that patients should be monitored closely for a 48 hour period at least.
Plasma clearance of gliclazide may be prolonged in patients with hepatic disease. However, due to the strong binding of gliclazide to proteins, dialysis is not effective in these patients.
For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Gliclazide reduces blood glucose levels by stimulating insulin secretion from the β-cells of the islets of Langerhans. Gliclazide shows high affinity, strong selectivity and reversible binding to the β-cell KATP channels with a low affinity for cardiac and vascular KATP channels. Increased postprandial insulin and C-peptide secretion persists after two years of treatment.
In type II diabetes, gliclazide restores the first-peak of insulin secretion in response to glucose and increases the second phase of insulin secretion. A significant increase in insulin release is seen in response stimulation induced by a meal or glucose.
Gliclazide also has extra-pancreatic effects and haemovascular properties.
It has been shown to increase peripheral insulin sensitivity:
In muscle, euglycaemic hyperinsulinaemic clamp studies with gliclazide have demonstrated significantly increased (35%) insulin mediated glucose uptake which may improve diabetes control. Gliclazide potentiates insulin action on muscle glycogen synthase. These effects are consistent with a post-transcriptional action of gliclazide on GLUT4 glucose transporters.
Studies on glucose turnover have further shown that gliclazide decreases hepatic glucose production, leading to an improvement in fasting blood glucose levels.
Gliclazide has been shown in some studies to have actions independent of that on glucose levels. These haemovascular effects of gliclazide include:
Partial inhibition of platelet aggregation and adhesion with a decrease in markers of platelet activation (beta-thromboglobulin, thromboxane B2).
Increased vascular endothelial fibrinolytic activity (increased tPA activity).
Anti-oxidant properties, notably a reduction in plasma lipid peroxides and increased erythrocyte superoxide dismutase activity.
Inhibition of the increased adhesiveness of type II diabetic patient's monocytes to endothelial cells in vitro.
The anti-oxidant, platelet inhibiting and fibrinolytic actions of gliclazide involve processes which have been implicated in the pathogenesis of vascular complications of type II diabetes. There is no clinical evidence that the haemovascular effects of gliclazide are of therapeutic benefit in type II diabetes patients.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Absorption.

Gliclazide is absorbed in the gastrointestinal tract reaching peak serum concentrations within 4 to 6 hours.
Single dose studies have demonstrated that maximal falls in blood glucose levels (23% of an 80 mg dose; 30% of a 160 mg dose) occur approximately five hours after drug administration; nine hours after a dose of 160 mg, a reduction of 20% was still in evidence.
The half-life of gliclazide is approximately 12 hours.

Distribution.

Gliclazide is distributed to the extracellular fluid. In animals, high concentrations of the drug were found in the liver, kidneys, skin, lungs, skeletal muscle, intestinal and cardiac tissue. Penetration of gliclazide into the central nervous system was negligible. Gliclazide crosses the placental barrier and penetrates the foetus. The apparent volume of distribution of gliclazide (20 to 40% expressed as a percentage bodyweight) is low and probably reflects the high degree of protein binding (94.2% at a plasma concentration of approximately 8 microgram/mL).

Metabolism.

Little information is available in the metabolism of gliclazide. At least eight metabolites (three major) have been identified by thin layer and gas-liquid chromatography. Some of these are glucuronic acid conjugates; only one of the metabolites has been identified (p-toluene sulfonamide). The liver is the probable site of metabolism.

Excretion.

Approximately 70% of the administered dose appears to be excreted in the urine and 11% in the faeces. The urinary excretion of the drug is slow and the maximum rates do not occur until 7 to 10 hours after initial administration. The metabolic products are detectable in the urine 120 hours after oral administration. Faecal elimination is usually complete within 144 hours of oral administration.

5.3 Preclinical Safety Data

Genotoxicity.

In animal studies embryotoxicity and/or birth defects have been demonstrated with some sulphonylureas.
Animal studies of gliclazide have not shown any teratogenic effect.

Carcinogenicity.

No data available.

6 Pharmaceutical Particulars

6.1 List of Excipients

Croscarmellose sodium, lactose monohydrate, magnesium stearate, colloidal anhydrous silica, microcrystalline cellulose.

6.2 Incompatibilities

See Section 4.5 Interactions with Other Medicines and Other Forms of Interactions.

6.3 Shelf Life

In Australia, the information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C.

6.5 Nature and Contents of Container

80 mg tablets.

Blister pack (PVC/Aclar clear/Aluminium silver foil) in cartons of 100 tablets. AUST R 80084.
Not all packs sizes and/or pack types may be available.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

Chemical structure.


Chemical Name: 1-(3-azabicyclo[3.3.0] oct-3-yl)-3-p-tolylsulphonylurea.
Chemical Formula: C15H21N3O3S.
Molecular Weight: 323.4.

CAS number.

21187-98-4.

7 Medicine Schedule (Poisons Standard)

S4 - Prescription Only Medicine.

Summary Table of Changes